Project information
NGS-PTL - Next Generation Sequencing platform for targeted Personalized Therapy of Leukemia
(NGS-PTL)
- Project Identification
- 306242
- Project Period
- 11/2012 - 10/2015
- Investor / Pogramme / Project type
-
European Union
- 7th Specific RTD Programme
- Cooperation
- MU Faculty or unit
- Central European Institute of Technology
- Cooperating Organization
-
Institute of Postgraduate Education in Medicine Prague
Universität Ulm
Universita di Bologna
- Responsible person prof. Giovanni Martinelli
Hematological diseases are highly heterogeneous malignancies in the matter of the molecular mechanisms related to their development and progression. A considerable heterogeneity can be further observed within the same hematological disease at the inter-individual level, being reflected by different clinical outcomes and responses to treatment in different patients. Nowadays the advent of high-throughput sequencing (HTS) technologies that are revolutionizing genomics and transcriptomics by providing a single base resolution tool for a unified deep analysis of diseases complexity allows a fast and cost-efficient fine-scale assessment of the genetic/genomic variability hidden within cohorts of patients affected by the same leukemia. That being so, by potentially highlighting inter-individual differences that may play a role in the differential success of diverse therapeutic interventions, they promise to be crucial for selecting the most appropriate medical treatments. This project aims at developing a European Hematological/HTS platform of scientists for improving outcomes for therapeutic interventions on acute and chronic leukemias and at develop strategies to personalize treatments and tailor therapies to different stratified groups of leukemia patients, with the goal of optimizing their efficacy and safety through a deeper and deeper understanding of the influence of genetic/genomic alterations on leukemias pathogenesis and treatment response (i.e. “personalized therapy”). Moreover, the final aim will be the identification of novel prognostic biomarkers for acute and chronic leukemias, as well as of molecular biomarkers and/or genomic profiles for the assessment of minimal residual disease. The originality of this project is to perform systematic deep genomic/transcriptomic studies on well-clinically-characterized leukemia patients, by exploiting HTS technologies able to quickly produce data with a good cost-effectiveness and an unprecedented resolution.
Publications
Total number of publications: 18
2016
-
Analysis of clonal evolution in chronic lymphocytic leukemia from inactive to symptomatic disease prior treatment using whole-exome sequencing.
Year: 2016, type: Conference abstract
-
The expression of CD20 on malignant B cells is regulated by chemokine signaling through the CXCR4/SDF1 axis: implications for targeting the microenvironmental interactions.
Year: 2016, type: Conference abstract
2015
-
13Q deletion in predominant cytogenetic aberration newly aquired during chronic lymohocytic leukemia course irrespective of disease activity and treatment status.
Year: 2015, type: Conference abstract
-
Focal adhesion kinase regulation and expression in malignant B cells
Year: 2015, type: Conference abstract
-
Microenvironmental interactions up-regulate CD20 expression in CLL B cells through the CXCR4/SDF-1 axis: implications for CD20-targeting antibodies and the use of BCR-inhibitors in combination.
Year: 2015, type: Conference abstract
-
Microenvironmental interactions up-regulate CD20 expressionin CLL B cells, but confer resistance to rituximab
Year: 2015, type: Conference abstract
-
MicroRNA involvement in DNA damage response and BCR signaling in malignant B cells
Year: 2015, type: Conference abstract
-
MicroRNA-150 influences microenvironmental interactions and prognosis of follicular lymphoma
Year: 2015, type: Conference abstract
-
MicroRNAs in DNA damage response and BCR signaling in malignant B cells.
Year: 2015, type: Conference abstract
-
Mutations in the TP53 gene show features of somatic hypermutation process with prominent difference between IGHV mutated and unmutated chronic lymphocytic leukemia.
Year: 2015, type: Conference abstract